News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genmab A/S (GEN.CO), GlaxoSmithKline (GSK) (JOBS) Cancer Drug Arzerra Disappoints in Phase 3 Study


8/18/2009 6:42:18 AM

Bookmark and Share

Reuters -- Disappointing clinical results sent shares in Danish biotechnology company Genmab tumbling 26 percent on Tuesday as investors questioned sales prospects for its key drug Arzerra in treating blood cancer.

Read at Reuters
Read at Wall Street Journal

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES